Veracyte
Veracyte, Inc., a leading genomic diagnostics company headquartered in the United States, is at the forefront of transforming patient care through innovative solutions. Founded in 2013, Veracyte has made significant strides in the field of molecular diagnostics, particularly in oncology and pulmonary diseases. The company’s core offerings include advanced genomic tests that provide critical insights for accurate disease diagnosis and management, setting them apart in a competitive market. With a strong presence in the US and expanding operations globally, Veracyte has established itself as a trusted partner for healthcare providers. Notable achievements include the development of unique tests that enhance the diagnostic process, thereby improving patient outcomes. As a pioneer in the industry, Veracyte continues to lead the way in precision medicine, making significant contributions to the evolving landscape of genomic healthcare.
DitchCarbon Score
How does Veracyte's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Veracyte's score of 3 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Veracyte's reported carbon emissions
Veracyte, Inc., headquartered in the United States, currently does not have publicly available carbon emissions data for the most recent year. However, the company is committed to reducing its carbon footprint and has made strides in establishing its climate commitments. As of May 2024, Veracyte has committed to near-term reduction targets, although specific numerical targets have not been disclosed. The company is actively engaged in initiatives aimed at minimising its environmental impact, particularly within the healthcare sector, which is increasingly focused on sustainability. While Veracyte has not yet set a net-zero target, its commitment to reducing emissions aligns with industry standards and reflects a growing trend among healthcare providers and technology firms to address climate change. The company’s efforts are part of a broader movement within the sector to enhance sustainability practices and reduce greenhouse gas emissions. In summary, while specific emissions data is not available, Veracyte is taking steps towards climate responsibility through its commitment to reduction targets, contributing to a more sustainable future in healthcare.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Veracyte is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
